Please assess the completion status of the following clinical trial:

Trial Title: Bovine Lactoferrin to Prevent and Cure Iron Deficiency and Iron Deficiency Anemia in Complicated Pregnancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* pregnant women with one of genetic thrombophilia markers as factor V Leiden, prothrombin 20210A mutation, antiphospholipid antibodies, hyperhomocysteinemia and deficiencies of antithrombin, protein C, or protein S.~* pregnant women affected by HT and suffering of iron deficiency (ID) and iron deficiency anemia (IDA)~* different trimester of pregnancy~* previous miscarriage/s~* previous preterm delivery/ies~* iron disorders as iron deficiency and iron deficiency anemia are defined by the number of red blood cells \<4.000.000/mL, the hemoglobin concentration ≤ 11 g/dL, the total serum iron ≤ 30 mg/dL and serum ferritin ≤12 ng/mL.~Exclusion Criteria:~* absence of iron deficiency and iron deficiency anemia~* non-pregnant women~* uncomplicated pregnancies~* no informed consent~* other treatments of iron supplementation~* recent blood transfusion~* other concomitant diseases~* ascertained allergy to milk proteins or to iron products.

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Lactoferrin treatment in HT pregnacies (Type: EXPERIMENTAL): Pregnant women affected by HT, ID and IDA are enrolled and treated until delivery with oral administration of one capsule of 100 mg of bLf (Lattoglobina, Grunenthal, Italy) twice a day before meals. In twin pregnancies or in severe anemia, HT pregnant women are treated until delivery with two capsules of 100 mg of bLf twice a day, before meals.
- Ferrous sulfate in HT pregnancies (Type: ACTIVE_COMPARATOR): Pregnant women affected by HT, ID and IDA are enrolled and treated until delivery with oral administration of 520 mg of ferrous sulfate (Ferro-Grad, Abbott Laboratories, USA), once a day during meal.

Based on this trial design, predict the completion outcome and termination type (if applicable).